Company news

uniQure N.V. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

uniQure to Participate in Multiple Upcoming Industry Conferences in October

September 29, 2021

uniQure to Participate in Multiple Upcoming Industry Conferences in September

September 6, 2021

uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

August 29, 2021

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

July 25, 2021

uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress

July 1, 2021

uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)

June 21, 2021

uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update

June 21, 2021

uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

June 15, 2021

uniQure to Participate in Multiple Upcoming Industry Conferences in June

June 1, 2021

uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

May 26, 2021

uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector

May 12, 2021

uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress

May 9, 2021

uniQure announces closing of commercialization and license agreement with CSL Behring

May 5, 2021

uniQure to Participate in Multiple Upcoming Industry Conferences in May

May 2, 2021

uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

April 27, 2021

uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program

April 25, 2021

uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain

April 7, 2021

uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

April 4, 2021

uniQure to Participate in Multiple Upcoming Industry Conferences in April

March 31, 2021

uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program

March 28, 2021

uniQure Announces 2020 Financial Results and Highlights Recent Company Progress

February 28, 2021

uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

February 7, 2021

uniQure to Participate in Multiple Upcoming Industry Conferences in February

January 31, 2021

uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program

December 20, 2020

uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology

December 7, 2020

uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B

December 6, 2020

uniQure to Participate in Multiple Upcoming Industry Conferences in December

December 1, 2020

uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting

November 29, 2020

uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

November 18, 2020

uniQure to Participate in Multiple Upcoming Industry Conferences in November

November 3, 2020

uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting

November 3, 2020

uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress

October 26, 2020

uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

October 12, 2020

uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

September 24, 2020

uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development

August 25, 2020

uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress

July 29, 2020

← Newer news releases

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.